MedTrace Logo

68Ga-NODAGA-RGD PET/ CT for Tumoral Neoangiogenesis

NCT02666547 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2024-06-20

No results posted yet for this study

Summary

This study will assess the potential of the 68Ga-NODAGA-RGD for the evaluation of neoangiogenesis in patients followed for a neoplastic pathology and for whom a18F-FDG (or 18F-FET for gliomas) is indicated for initial extension evaluation or suspicion of recurrent tumor.

Conditions

  • Pathological Angiogenesis

Interventions

DRUG

68Ga-NODAGA-RGD PET/CT

200 MBq 68 Ga-NODAGA-RGD will be administered i.v. and images acquired on all body . For glioma, images acquired centred on the skull

RADIATION

18F-FDG PET/CT

3.5 MBq/kg 18F-FDG will be administered i.v. and images acquired on all body

RADIATION

18F-FET PET/CT

200 MBq 18F-FET will be administered i.v. and images acquired centred on the skull

Sponsors & Collaborators

  • George Coukos, MD PhD, Head of oncology

    collaborator UNKNOWN

  • University of Lausanne Hospitals

    lead OTHER

Principal Investigators

  • John O Prior, MD, PhD · Lausanne University Hospitals

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-03-31
Primary Completion
2023-08-31
Completion
2023-09-30

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02666547 on ClinicalTrials.gov